<DOC>
	<DOCNO>NCT00551070</DOCNO>
	<brief_summary>This phase II trial study side effect well selumetinib work treat patient recurrent low-grade ovarian cancer . Selumetinib may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Selumetinib Treating Woman With Recurrent Low-Grade Ovarian Cancer Peritoneum Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To examine tumor response rate patient AZD6244 ( selumetinib ) ( NSC # 748727 ) . II . To examine acute toxicity AZD6244 ( NSC # 748727 ) first course treatment use CTCAE version 3.0 . III . To define pharmacokinetic profile AZD6244 , 100 mg administer orally twice daily . SECONDARY OBJECTIVES : I . To examine toxicity AZD6244 ( NSC # 748727 ) use 21 major category CTCAE version 3.0 . II . To examine dose number course AZD6244 ( NSC # 748727 ) give . III . To estimate progression free survival , overall survival woman receive AZD6244 ( NSC # 748727 ) . TERTIARY OBJECTIVES : I . To examine DNA isolation sequence braf , ras mutation analysis explore relationship tumor response AZD6244 ( NSC # 748727 ) . II . To examine protein level p-ERK/ERKERK explore relationship tumor response patient treat AZD6244 ( NSC # 748727 ) . OUTLINE : This multicenter study . Patients receive selumetinib orally ( PO ) twice day day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo blood sample collection periodically correlative pharmacokinetic study analyze selumetinib peak concentration correspond peak time value . Previously collect archived tumor tissue sample obtain determine protein level p-ERK/ERKERK , DNA isolation sequence BRAF ras mutation analysis immunohistochemistry ( IHC ) . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , year 5 year .</detailed_description>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<criteria>Meeting 1 follow diagnosis : Lowgrade ovarian carcinoma recur lowgrade serous carcinoma ( invasive micropapillary serous carcinoma invasive grade I serous carcinoma define GOG , FIGO WHO , S. G. Silverberg ) peritoneal carcinoma Serous borderline ovarian carcinoma recur lowgrade serous carcinoma ( invasive micropapillary serous carcinoma invasive grade I serous carcinoma define GOG , FIGO WHO , S. G. Silverberg ) peritoneal carcinoma Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique include palpation , plain xray , CT scan , MRI scan , OR ≥ 10 mm spiral CT scan Patients whose primary tumor serous borderline ovarian carcinoma , lowgrade serous ovarian carcinoma , peritoneal carcinoma must pretreatment sample tumor primary recurrent tumor document low grade serous carcinoma ( invasive micropapillary serous ) No know brain metastasis GOG performance status 01 Platelet count ≥ 100,000/mm³ ANC count ≥ 1,500/mm³ Bilirubin &lt; 1.5 time upper limit normal ( ULN ) Creatinine &lt; 1.5 time ULN Transaminases &lt; 2.5 time ULN Neuropathy ≤ grade 1 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception prior , , 4 week completion study therapy QTc interval ≤ 450 msec factor increase risk QT prolongation arrhythmic event include , limited , follow : Heart failure Hypokalemia Family history long QT interval syndrome NYHA class IIIIV heart failure No history allergic reaction attribute compound similar chemical biological composition AZD6244 excipient Captisol No refractory nausea vomiting , chronic gastrointestinal disease ( e.g. , inflammatory bowel disease ) , significant bowel resection would preclude adequate absorption No uncontrolled intercurrent illness include ongoing active infection , psychiatric illness , social situation would limit compliance study requirement More 4 week since prior chemotherapy radiotherapy ( 6 week nitrosoureas mitomycin C ) recover No prior AZD6244 No prior MEK inhibitor No HIVpositive patient combination antiretroviral therapy No concurrent medication potential prolong QT interval No concurrent drug know affect potential affect select CYP450 isoenzymes No concurrent grapefruit grapefruit juice AZD6244 administration No concurrent investigational commercial agent cancer</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>